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CHAPTER 1 
 INTRODUCTION 
 
1.1 Apoptosis 
Apoptosis, or programmed cell death (PCD), is an essential mechanism for the 
regulation of cellular homeostasis and normal development. Apoptosis requires precise 
regulatory and signaling pathways to orchestrate the timing and progression of cell death. 
Among the processes dependent upon apoptosis are organ formation and regulation of the 
immune system, as well as successful completion of embryo development (1, 2). 
Apoptosis is characterized by various biochemical and morphological changes, including 
DNA fragmentation, plasma membrane blebbing, and the externalization of signaling 
molecules such as phosphatidylserine, which lead to the formation of apoptotic bodies 
(3). Of particular importance is the deregulation of apoptosis. The failure of a cell to 
undergo apoptosis is central to cancer progression and chronic inflammatory diseases. On 
the contrary, uncontrolled apoptosis may lead to neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s (4-6). 
Apoptosis is executed by a family of conserved cysteine proteases called 
caspases. Caspases involved in apoptosis are characterized into two groups, the initiator 
caspases, such as caspase-8 and caspase-9, and the effector caspases, such as caspase-3 
and caspase-7. All caspases are synthesized in cells as inactive precursors called pro-
caspases that become activated by various apoptotic stimuli (7-9). Activation is induced 
through a series of proteolytic cleavages that result in an assembly of tetramers. The 
activation of an effector caspase is performed by an initiator caspase through an internal 
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cleavage to separate the large and small subunits. The activation of an initiator caspase, 
however, is autoactivated under apoptotic conditions and usually facilitated by large 
multicomponent complexes often called apoptosomes (10). The active enzymes are 
heterotetramers composed of two identical subunits of ~20 kDa and two identical 
subunits of ~10 kDa, whereas the prodomain or amino-terminal domain is usually 
cleaved during activation (11). Initiator caspases typically contain an extended N-
terminal prodomain that is important for protein-protein interactions. In contrast, effector 
caspases typically contain a shortened prodomain often implicated in binding to 
regulatory proteins (12). All known caspases possess an active-site cysteine, and cleave 
substrates after aspartic residues at Asp-Xxx bonds; the distinct substrate specificity of 
caspases is determined by the four residues amino-terminal to the cleavage site (13). 
Cleavage induces activation or inactivation of substrates that results in the characteristic 
biochemical changes that progress cells towards death through the formation of apoptotic 
bodies (3). 
Two main pathways exist for caspase activation: the extrinsic pathway and the 
intrinsic pathway. The extrinsic pathway, or the receptor mediated-pathway, involves the 
binding of apoptotic stimuli to a receptor, such as the Fas receptor, that contains a 
cytoplasmic death domain essential for transduction of the apoptotic stimuli. Receptor-
ligand association promotes the formation of an intracellular complex of adaptor proteins 
including FADD (Fas-associated death domain) which triggers the recruitment of pro-
caspase-8 and the subsequent activation of the caspase cascade (14, 15). In contrast, the 
intrinsic pathway is receptor-independent and is commonly initiated by mitochondrial 
dysfunction. Apoptotic stimuli, such as cytotoxic drugs, produce changes in the 
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mitochondrial membrane potential which allows for the leakage of pro-apoptotic 
molecules such as cytochrome c, into the cytoplasm, promoting the activation of caspase-
9. Released cytochrome c binds to Apaf-1 and the cofactor dATP, resulting in the 
formation of the apoptosome. Together, these molecules allow for the activation of 
caspase-9 (16). The activation of caspase-9 can also be accomplished through the 
receptor-mediated pathway following the activation of caspase-8 (17) serving as a means 
of communication between the intrinsic and extrinsic apoptotic pathways. In addition to 
cytochrome c, radical oxygen species (ROS) are often released from the mitochondria 
due to disruption of the electron transport chain (18) and contribute to the activation of 
the apoptotic program (19).  Regardless of the pathway, however, signaling cascades 
converge on the activation of downstream effector caspases such as caspase-3, -6, and -7  
(20), which are collectively responsible for the cleavage of target proteins and the 
subsequent biochemical changes accompanying apoptosis (21-23).  
In addition to caspase activation, cell response to apoptotic-inducing drugs has 
been associated with the activation of apoptotic kinases and the inactivation of survival 
kinases. The mitogen-activated protein kinase family (MAPK), which includes p38, JNK 
(Jun-N-terminal kinase), and ERK (extracellular signal-regulating kinase), has been 
implicated in cell proliferation, cell survival, and stress response (24). For instance, 
activation of p38 is associated with the induction of apoptosis in response to UV 
treatment and treatment with chemotherapeutic drugs (25, 26). By contrast, ERK can 
exhibit either anti-apoptotic or pro-apoptotic functions depending on the stimuli and cell 
type. In monocytes, ERK phosphorylation has been shown to inhibit caspase-9 activation 
and therefore apoptosis (27). However, up-regulation of ERK is associated with 
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apoptosis, especially during treatment with flavonoids (28). In addition to MAPKs, 
members of the protein kinase C family (PKC) have been shown to regulate cell death. In 
particular, PKCδ has been suggested as a pro-apoptotic molecule as PKCδ activation has 
been associated with cell death in various cell types in response to a variety of apoptotic 
stimuli (29). For instance, PKCδ has been shown to phosphorylate and activate caspase-3 
(30). PKCδ has also been identified as a substrate of caspase-3 and its proteolytic 
cleavage results in a constitutively active catalytic domain necessary for apoptosis (31, 
32). Additionally, PKCδ has been shown to translocate to the mitochondria and alter its 
membrane potential (33) and promote ROS production (34, 35). 
 
1.2 Flavonoids 
Increasing attention has been focused on the use of compounds derived from 
fruits and vegetables for epidemiological purposes such as cancer prevention and 
oxidative stress protection. The principal plant-derived agents thought to provide cancer 
prevention and antioxidant properties are flavonoids, which are the most common and 
widely distributed polyphenolic compounds, ubiquitously present in foods of plant 
origins (36). Flavonoids are composed of a common phenyl chromanone structure with 
one or more hydroxyl substitutes (Fig 1.1). Depending on the organization of their 
benzene rings and their modifications, flavonoids are generally classified into flavones, 
flavanols, isoflavones, flavanols, flavanones, and anthocyanins (36, 37). Flavonoids have 
long been recognized as having anti-cancer, anti-inflammatory, anti-viral, anti-bacterial, 
and anti-allergic properties (38-40). For example, the flavanone naringenin, which is 
found abundantly in grapefruits, has been shown to have an anti-
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Figure 1.1 Structure of typical flavonoid (top) and apigenin (bottom) 
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carcinogenic effect in breast cancer (41).  The flavone apigenin, which is found 
abundantly in broccoli, parsley, and chamomile tea, has been reported to induce apoptosis 
in breast cancer, colon cancer and lymphocytic leukemia (42-44). In particular, apigenin 
has been shown to induce mitochondrial depolarization and the production of reactive 
oxygen species which allows for the release of cytochrome c and procaspase-9 from the 
mitochondria and the induction of the caspase-dependent apoptotic pathway (44-46). 
Recently, a role for apigenin in monocytic leukemia cells was identified. It was shown 
that apigenin localizes to the mitochondria of leukemia cells and stimulates the apoptotic 
pathway in a PKCδ and caspase-dependent mechanism. However, in contrast to many 
other cell types, ROS production and MAPK activation were shown to act independently 
of apoptosis induction (47). In addition, there is very little evidence to suggest that 
apigenin produces adverse metabolic effects when consumed in nutritionally relevant 
quantities. In fact, it has been shown that apigenin reduces proliferative properties of 
leukemia cells at a much greater capacity than the flavonoid’s effect on the epithelial 
cells MCF7 and A549 (47). Therefore, the use of apigenin as a chemopreventive agent 
may provide a tissue-specific defense against cancer and oxidative stress. 
 
1.3 The small heat shock protein Hsp27 
The small heat shock protein 27 (Hsp27) belongs to a family of molecular 
chaperones that have recently been focused on as regulators of cell death and survival. 
Hsps encompass several groups of proteins and are classified by size, structure, and 
function: Hsp110, Hsp90, Hsp70, Hsp60, and the small Hsp families (48). Some Hsps are 
constitutively expressed and increase in response to environmental and physiological 
9 
 
stress. In unstressed cells, Hsps are essential for maintaining cellular homeostasis, 
functioning as molecular chaperones to help facilitate protein folding (49-51).   
 The small heat shock proteins (sHsps) are low molecular mass chaperones 
ubiquitously present throughout all kingdoms. The sHsps are ATP-independent 
chaperones characterized by a conserved crystallin domain flanked by variable N- and C-
terminal regions (52, 53). In unstressed cells, sHsps exist as large oligomeric complexes 
whose oligomerization state is dependent on the degree of phosphorylation of the 
individual monomers. Phosphorylation at the N-terminus results in a redistribution of the 
large oligomer into smaller tetramer units whereas dephosphorylation promotes the 
formation of large oligomers (54, 55). It is thought that the chaperone activity of sHsps is 
correlated with this dynamic oligomerization. Exposure to stress promotes the formation 
of misfolded proteins that may bind large non-phosphorylated sHsp oligomers or smaller 
complexes such as dimers to prevent aggregation. Upon return to favorable conditions, 
these proteins are released and either refold spontaneously or with the help of the ATP-
dependent chaperones such as Hsp70 (56).  
More recently, focus has shifted towards the potential anti-apoptotic functions of 
the sHsps, with a particular emphasis on Hsp27. Hsp27 is known to block apoptosis at 
different stages due to its interaction with other proteins. As a molecular chaperone, 
Hsp27 plays an important role in the prevention of protein aggregates following 
misfolding. Sufficiently large amounts of misfolded proteins can result in the formation 
of these aggregates, which can signal for the induction of apoptosis (50, 51). Hsp27 can 
also protect against protein aggregation at the pre-translational level by binding to the 
translation initiation factor eIF4G and preventing the translation of mRNAs under 
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stressful conditions, a common cause of protein misfolding (49). Additionally, Hsp27 has 
been shown to protect against apoptosis by regulating mitochondrial dysfunction through 
inhibition of ROS production and mitochondrial membrane depolarization (34, 57-59). 
However, Hsp27 primarily exhibits its anti-apoptotic effect through direct interaction 
with several critical components of the apoptotic pathway (Fig 1.2). Following extrinsic 
stimuli, Hsp27 has been shown to exhibit its anti-apoptotic effect in a mitochondrial and 
caspase-independent manner by blocking the interaction of Daxx with the Fas death 
receptor (60). More importantly, Hsp27 functions as a negative regulator of the leakage 
of pro-apoptotic molecules normally residing in the mitochondria, which can result in 
caspase-3-dependent apoptosis. Hsp27 inhibits caspase-3 activation by sequestering pro-
caspase-3 and cytochrome c (61), negatively regulating the activation of the pro-caspase-
9 through interaction with cytochrome c (62), and inhibiting the activation of the pro-
apoptotic Bax through a PI3K-dependent mechanism (63). Hsp27 has also been shown to 
regulate apoptosis by binding to the prodomain of caspase-3, inhibiting its activation 
(64). Thus, Hsp27 exhibits a robust anti-apoptotic activity with many members of the 
apoptotic pathway and many potential points of regulation.    
It is recognized that interaction of Hsp27 with other proteins is regulated by the 
oligomerization and phosphorylation status of the protein. It has been suggested that large 
non-phosphorylated oligomers of Hsp27 are required for its caspase-dependent anti-
apoptotic activity (65).  Moreover, it has been shown that phosphorylation is responsible 
for the release of Hsp27 from its target proteins through dissociation into smaller 
multimers (55, 66). Hsp27 is phosphorylated at three different serine residues, Ser-15, 
Ser-78, and Ser-82, by mitogen-activated protein kinase-activated protein kinase 2 (MK2)  
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Figure 1.2 Anti-Apoptotic functions of Hsp27 
Hsp27 can regulate apoptosis various points. Following extrinsic activation of the 
apoptotic pathway, Hsp27 can block Daxx-mediated apoptosis by preventing the 
translocation of Daxx to the plasma membrane and its association with the Fas receptor. 
Hsp27 also acts as a negative regulator of the leakage of pro-apoptotic molecules from 
the mitochondria by maintaining intracellular redox homeostasis and mitochondrial 
stability. Following stress-induced release of pro-apoptotic molecules from the 
mitochondria, Hsp27 can inhibit Bax in a PI3K-dependent mechanism and sequester 
cytochrome c release from the mitochondria. In addition, Hsp27 can regulate caspase 
activation both by preventing caspase-9 activation by association with cytochrome c and 
by binding to the prodomain of caspase-3. 
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as a result of p38 MAPK pathway activation (67, 68). Additionally, it has been found that 
PKCδ may act as an upstream kinase of p38, inducing the phosphorylation of Hsp27 by 
MK2 (69), or as the kinase directly responsible for Hsp27 phosphorylation (66, 70). 
Although p38 has been identified as the primary upstream kinase involved in MK2 
activation, other families of MAPKs may play a role in Hsp27 phosphorylation. In 
particular, ERK has been identified as both a kinase responsible for MK2 
phosphorylation (71) and a substrate of PKCδ (72). Therefore, the kinases involved in 
Hsp27 phosphorylation may exhibit both cell and stimulus specificity. 
In this work, we sought to determine the regulators of Hsp27 phosphorylation 
during apigenin-induced apoptosis. Additionally, we sought to determine the role of 
Hsp27 phosphorylation in the chaperone’s ability to protect against mitochondrial 
membrane depolarization. We first demonstrated that Hsp27 exhibits a bimodal 
phosphorylation during apigenin-induced apoptosis. We found that following a 15 min 
apigenin treatment, Hsp27 phosphorylation is p38 dependent. Additionally, we found that 
at 6 h post-apigenin treatment, Hsp27 phosphorylation at both Ser-78 and Ser-82 is p38 
dependent. Moreover, we found that at 6 h, only Ser-82 is PKCδ dependent and full-
length PKCδ can directly and specifically phosphorylate Hsp27 at Ser82. Furthermore, 
we found that p38 may act upstream of PKCδ during this phosphorylation event. Finally, 
we found that protection against mitochondrial depolarization is independent of Hsp27 
phosphorylation. Collectively, these results suggest an intimate association among p38, 
PKCδ, and Hsp27 and uncover a novel bimodal phosphorylation pattern in Hsp27, further 
elucidating the mechanism by which apigenin regulates cell death. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
2.1 Materials and cell culture  
 
All cell lines were grown at 37 °C in a humidified atmosphere of 95% air and 5% 
CO2 in media supplemented with 100 μg/mL penicillin, and 100 μg/mL streptomycin 
(P/S; BioWhittaker, Walkersville, MD).  Monocytic leukemia THP-1 cells were 
maintained in RPMI 1640 medium with L-glutamine (BioWhittaker) supplemented with 
5% fetal bovine serum (FBS) (Hyclone, Logan, UT). For all experiments, cells were 
seeded at a concentration of 0.5 x 106 cells/mL 24 h prior to treatment. Apigenin, the 
diluent dimethyl sulfoxide (DMSO), the phosphatase inhibitors: Na-glycerophosphate, 
Na-pyrophosphate, NaF, orthovanadate; dithiothreitol (DTT), and the protease inhibitors: 
phenylmethyl sufonyl fluoride (PMSF), chymostatin, pepstatin, leupeptin, antipain were 
obtained from Sigma-Aldrich (St. Louis, MO).  The substrate of caspase-3, DEVD-AFC 
(AFC138), and the caspase-3 inhibitor, DEVD-FMK (FMK109), were obtained from MP 
Biomedicals (Solon, OH).  The inhibitors of p38, SB203580 (559389), MEK-1, PD98059 
(513000), and the PKCδ  inhibitor, rottlerin (557370), were obtained from Calbiochem 
(San Diego, CA). 
 
2.2 Immunoblot and coomassie staining 
 
Whole cell lysates were prepared by vortexing in Buffer B (50 mM HEPES pH 
7.4, 2.5 mM EGTA, 1 mM EDTA, 150 mM NaCl, 10% Glycerol, 0.1% Tween 20 
containing 50 mM NaF, 10 mM Na glycerophosphate, 5 mM Na pyrophosphate, 1 mM 
orthophosphate, 1 mM DTT, 0.1 mM PMSF, 2 μg/ml of protease inhibitors: chymostatin, 
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pepstatin, leupeptin, antipain and phosphatase inhibitors) for 1 h at 4 oC. Lysates were 
then centrifuged at 13,200 x g for 10 min at 4 oC.  Supernatants were removed from 
pellets and stored at -80 oC until further analysis. Polypeptides from equal amounts of 
protein, as determined by the Bradford method, were separated by SDS-PAGE.  Gels 
were stained over night with Coomassie stain (0.025% (w/v) Coomassie G-250, 45% 
(v/v) methanol, 10% (v/v) glacial acetic acid) followed by destaining solution  (30% (v/v) 
methanol, 10% (v/v) glacial acetic acid).  For immunoblot analysis, polypeptides were 
transferred onto nitrocellulose membranes (25 mM Tris, pH 8.3, 192 mM glycine, 20% 
(v/v) methanol) and probed with antibodies of interest followed by horseradish 
peroxidase conjugated secondary antibody and visualized by enhanced 
chemiluminescence (Amersham, Arlington Heights, IL).  Immunoblot quantitation was 
performed with Biorad Quantity One software (Hercules, CA). Phospho-ERK (9101), 
total ERK (9102), phospho-p38 (9211), total p38 (9212), phospho-Hsp27 (Ser78) (2405), 
phospho-Hsp27 (Ser82) (2401), and total Hsp27 (2442) antibodies were obtained from 
Cell Signaling (Boston, MA).  PKCδ antibody (SC-937) was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA). β-Tubulin (05-661) was obtained from Upstate 
(Charlottesville, VA).  
 
2.3 Caspase-3 activity assay 
Lysates from 3 x 106 cells were prepared and incubated in a cytobuffer as 
previously described (27). The activity of caspase-3 in a 10 μg protein sample was 
determined using the DEVD-AFC substrate. Released AFC were measured using a 
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Cytofluor 400 fluorimeter (Filters: excitation 400 nm, emission 508 nm; Perspective Co., 
Framingham, MA).   
 
2.4 Immunoprecipitation and in vitro kinase assay and phosphorylation of 
recombinant Hsp27 
 
Following treatment with apigenin or DMSO, lysates were prepared as described 
for immunoblot analysis. Immunoprecipitation with anti-PKCδ antibodies were carried 
out as previously described (30).  After immunoprecipitation, kinase assays were 
performed by incubating protein A-loaded beads for 1 h at 37 °C in the presence of 20 μl 
kinase assay buffer (25 mM Hepes pH 7.3, 10 mM MnCl2, 1 mM MgCl2, 1 mM DTT) 
containing 5 μCi of {γ32P} ATP (Perkin Elmer, Boston, MA), 0.5 mM ATP.  To each 
reaction, 5 μg of histone H2B (Boehringer Mannheim, Roche, Indianapolis, IN) was 
added as exogenous substrate.  Reactions were stopped by the addition of 10 mL of 5X 
Laemmli buffer.  Samples were boiled for 5 min and loaded onto SDS-PAGE.  
For phosphorylation of recombinant Hsp27, recombinant PKCδ or heat-
inactivated recombinant PKCδ was incubated with recombinant wild-type Hsp27 for 1 h 
at 30 oC in the presence of 10 μL of kinase assay buffer containing 10 μCi of {γ32P} 
ATP. 
 
2.5 Bacterial cell culture 
Bacterial cells containing selected clones were cultured overnight at 37oC at 200 
rpm in 3-5 mL of LB media containing an appropriate putative antibiotic for selection. 
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2.6 DNA purification and restriction enzyme digestion 
Plasmid DNA was purified (45) for screening and transfections using QIAprep 
Miniprep Kit (QIAGEN, Valencia, CA) and eluted in 50 μL dH2O. Plasmids were 
digested with combinations of restriction enzymes (NEB, Beverly, MA) in bovine serum 
albumin (NEB, Beverly, MA), enzyme reaction buffer, (NEB, Beverly, MA), and dH2O 
for 2 hrs at 37 oC. 
 
2.7 Fragment isolation 
DNA was run on a 1% (w/v) agarose gel (Roche, Basel, Switzerland) containing 
ethidium bromide (0.5 μg/μL) (Sigma Aldrich Corp., St. Louis, MO) to stain the DNA.  
DNA was loaded with a 1 kb plus marker (Invitrogen, Carlsbad, CA) and electrophoresed 
for 40 min at 80 volts.  Fragments were purified from the agarose using a DNA gel 
extraction kit (QIAGEN).  
 
2.8 DNA ligation 
Vector and insert DNA were ligated to create a desired chimeric plasmid.  
Purified DNA insert fragments and vector were combined in a 2 to 1 ratio with T4 DNA 
ligase (1 U/uL) (Roche, Basel, Switzerland), T4 ligase reaction buffer [50 mM Tris-HCL, 
(pH 7.5), 10 mM MgCl2, 10 mM DTT, 1 mM ATP, 20 μg/ml BSA] (Roche, Basel, 
Switzerland) and dH2O in a 10 μL volume and incubated overnight at 16 oC.  
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2.9 Transformation of E. coli 
 Amplification of clones was carried out by transforming into 50 μL E. coli 
Top10F competent cells (Invitrogen).  Transformations were performed by combining 
ligation mixture (DNA, T4 ligase, ligation buffer, H2O) and cloning cells, E. coli Top10F 
for 30 min on ice.  Heat shock was performed at 42 oC for 1 min followed by incubation 
on ice for 2 min.  One mL S.O.C. media (2% Tryptone, 0.5% Yeast Extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) (Invitrogen) was 
added to mixture, and mixture was incubated at 37 oC and 200 rpm for 1 h. Cells were 
plated on LB-agar plates containing antibiotics specific to vector and grown overnight at 
37 oC. Colonies were screened by restriction analysis of miniprep DNA. 
 
2.10 Hsp27 purification under denaturing conditions 
 Bacteria containing 6xHis-tagged full-length Hsp27 3A (S15A, S78A, S82A) 
(pQE32-Hsp27 3A), or Hsp27 3D (S15D, S78D, S82D) (pQE32-Hsp27 3D) were grown 
in TB media with appropriate antibiotics and 2% (w/v) glucose to an OD of 
approximately A550 0.5. Protein expression was induced with 1mM IPTG for 3 h at 37 oC. 
Cells were collected and washed once in complete sonication buffer (50 mM sodium 
phosphate, pH 7.8, 300 mM NaCl, 5 mM β-mercaptoethanol, 1% Tween 20, and protease 
inhibitors (2 µg/mL chymostatin, pepstatin, leupeptin, antipain), and 1 mM PMSF). Cells 
were resuspended in buffer B (100 mM NaH2PO4, 10 mM Tris, 8 M urea, 1 μL/mL 
RNase and DNase, pH 8.0) and incubated for 30 min at rt. Cells were then sonicated until 
lysed. Lysates were allowed to bind to Ni2+-NTA beads (QIAGEN) in the presence of 
RNase and DNase (1 µL/mL) for 90 min at rt. After binding, the lysate-resin mixture was 
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loaded on an empty column and allowed to settle. The flow through was collected and the 
resin was washed twice with buffer C (100 mM NaH2PO4, 10 mM Tris, 8 M urea, 1 
μL/mL RNase and DNase, pH 6.3). Elutions were collected dropwise with buffer D (100 
mM NaH2PO4, 10 mM Tris, 8 M urea, 1 μL/mL RNase and DNase, pH 5.9) and buffer E 
(100 mM NaH2PO4, 10 mM Tris, 8 M urea, 1 μL/mL RNase and DNase, pH 4.5). Elution 
fractions containing recombinant Hsp27 were identified by SDS-PAGE.  The purified 
proteins underwent two series of dialysis. The buffer for the first dialysis consisted of 25 
mM NaH2PO4, 100 mM NaCl, 1% (v/v) Glycerol, 0.1 mM PMSF, pH 8.5. Dialysis was 
performed for 20 h at 4 oC, changing to fresh buffer after 3 h and again after 15 h. The 
buffer for the second diaysis consisted of 20 mM Tris pH 7.4, 10 mM NaCl, 1mM 
EDTA, 1 mM DTT.  Dialysis was performed for 4 h at 4 oC, changing the buffer three 
times during that time. Proteins were quantitated using a BSA standard and identified by 
immunoblot analysis. 
 
2.11 Transient Transfection 
Transfection of plasmids into THP-1 monocytic cells was performed as 
previously described (64). THP-1 cells were washed in PBS and resuspended in the 
specified electroporation buffer (Amaxa, Cologne, Germany) to a final concentration of 5 
x 106 cells/mL. One µg of empty vector (pCDNA3-5myc) and vector containing wild 
type full-length Hsp27 (pCDNA3-Hsp27-wt-FL-5myc), full-length Hsp27 3A (S15A, 
S78A, S82A) (pCDNA3-Hsp27-3A-FL-5myc), or Hsp27 3D (S15D, S78D, S82D) 
(pCDNA3-Hsp27-3D-FL-5myc) was mixed with 0.1 mL of cell suspension and 
nucleofected using the Amaxa NucleofectorTM according to manfacturer’s specification. 
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After transfection, the cells were immediately transferred into 3 mL of RPMI-medium 
with 10% (v/v) FBS and 1% (w/v) penicillin and streptomycin.   
 
2.12 Flow Cytometry  
Twenty-four hours after transfection, the cells were treated with 50 μM apigenin 
for 1 h to induce mitochondrial membrane depolarization. For detection of mitochondrial 
depolarization, a cell suspension was adjusted to a density of 1 x 105 cells/mL and 
incubated in annexin V binding buffer (BD Biosciences, Franklin Lakes, NJ) with 1% 
FBS for 15 min at room temperature in the dark with 5 μg/μL of the mitochondrial 
membrane potential specific fluorescent probe JC-1. Flow cytometry analysis was 
performed using BD Biosciences FACSCalibur using Cellquest version 3.3 software.  
 
2.13 Statistical Analysis 
All data are expressed as mean ± SEM and Student’s t-test comparisons were 
conducted to analyzed statistical significance.  Statistical significance is stated in the text. 
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CHAPTER 3 
 REGULATION OF HSP27 PHOSPHORYLATION DURING APIGENIN-
INDUCED APOPTOSIS 
 
 
Phosphorylation is known to be a critical and ubiquitous post-translational protein 
modification. Essential in signal transduction, phosphorylation has also been implicated 
in regulation of various proteins through the induction of conformational changes. Of 
particular interest, the phosphorylation of Hsp27 is thought to induce the dissociation of 
large Hsp27 oligomers to smaller multimers and dimers (73) and affect the affinity of the 
protein for its substrates (74). Therefore, phosphorylation, and the regulation of this 
phosphorylation, may play a critical role in Hsp27’s anti-apoptotic activity. In this aim, 
we seek to determine the molecules responsible for regulating Hsp27 phosphorylation 
during apigenin-induced apoptosis.  
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3.1 Hsp27 exhibits a bimodal phosphorylation profile during apigenin-induced 
apoptosis. 
 
It is known that Hsp27 becomes phosphorylated within minutes of exposure to 
stress (75) at three different serine residues, Ser-15, Ser-78, and Ser-82 with Ser-78 and 
Ser-82 being the most physiologically relevant phosphorylation sites (67, 68). In order to 
study the effect of apigenin on the phosphorylation status of Hsp27, we first determined 
the expression profile of phosphorylated Ser-78 and Ser-82 isoforms of Hsp27 during 
apigenin-induced apoptosis. For this purpose, THP-1 cells were treated with 50 μM 
apigenin for 0.25, 0.5, 1, 3, 6, and 9 h or with DMSO as diluent control for 9 h. Cell 
lysates were prepared and analyzed by immunoblot analysis. (Fig 3.1). We found that 
both phospho-Hsp27-S78 and phospho-Hsp27-S82 exhibit a bimodal expression profile 
during apigenin treatment. We observed that Hsp27 phosphorylation peaks at both serine 
residues 15 min post-apigenin treatment. Additionally, we also observed 
hyperphosphorylation at 6 h post-treatment following a period of diminished presence of 
the phosphorylated isoforms. Hsp27 is constitutively expressed and these levels remain 
constant throughout apigenin-induced apoptosis. 
 
3.2 Apigenin induces the activation of p38, ERK, and PKCδ. 
 
The involvement of the various members of the mitogen-activated protein kinase 
families, such as p38 and ERK, in promoting apoptosis is well characterized (76). 
Additionally, PKCδ is known to be a pro-apoptotic kinase in response to a variety of 
stimuli in a number of cell types (77). Therefore, these kinases may play yet 
uncharacterized roles during apigenin-induced apoptosis; in particular, through regulation 
of Hsp27. Phosphorylation of Hsp27 has been shown to be dependent upon p38  
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Figure 3.1 Hsp27 phosphorylation peaks at 15 min and 6 h following apigenin 
treatment 
Lysates from THP-1 cells cultured with 50 µM apigenin for 0.25, 0.5, 1, 3, 6, and 9 h or 
with DMSO as diluent control. Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 
Ser82, total Hsp27, and β-Tubulin. 
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activation of MK2 (67), direct interaction with PKCδ (66), and a signaling pathway 
involving both PKCδ and p38 (69). Moreover, ERK may play a role in Hsp27 
phosphorylation as it has been identified as both a kinase directly involved in the 
phosphorylation of MK2 (71) and as a substrate of PKCδ (72). Therefore, the nature of 
the kinases involved in Hsp27 phosphorylation may be stimulus specific. To investigate a 
potential role for these kinases in regulation of apigenin-induced Hsp27 phosphorylation, 
we first determined the expression profile of phospho-p38 and phospho-ERK following 
apigenin treatment. THP-1 cells were treated with 50 μM apigenin for different lengths of 
time or with DMSO as diluent control for 9 h. Cell lysates were prepared and analyzed by 
immunoblot analysis (Fig 3.2). We found that both p38 and ERK became 
hyperphosphorylated following apigenin treatment. As with Hsp27, we found that p38 
phosphorylation exhibits a bimodal expression profile which peaks at 15 min and 6 h. In 
contrast, we found that ERK phosphorylation increased through 6 h where it plateaus. 
Our results indicate a similarity between phosphorylation of p38 and Hsp27 at both 15 
min and 6 h post-apigenin treatment and between ERK and Hsp27 at 6 h post-treatment. 
Together these findings suggest potential roles for p38 and ERK in Hsp27 
phosphorylation.   
We next sought to determine the kinase activity of PKCδ during apigenin-induced 
apoptosis. THP-1 cells were treated with apigenin under similar conditions as above and 
cell lysates were prepared and analyzed by in vitro kinase assay to determine PKCδ’s 
ability to phosphorylate its substratre histone H2B (Fig 3.3). We found that PKCδ has 
maximal kinase activity 6 h post-apigenin treatment. In contrast, PKCδ has little kinase 
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Figure 3.2 p38 MAPK and ERK phosphorylation during apigenin-induced 
apoptosis 
Lysates from THP-1 cells cultured with 50 µM apigenin for 0.25, .5, 1, 3, 6, and 9 h or 
with DMSO as diluent control. Immunoblots with phospho-p38, phospho-ERK, total p38, 
total ERK, and β-Tubulin. 
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Figure 3.3 Kinase activity of PKCδ during apigenin-induced apoptosis 
 
Lysates from THP-1 cells cultured with 50 µM apigenin for 0.25, 0.5, 1, 3, 6, and 9 h or 
with DMSO as diluent control. Cells were immunoprecipitated (IP) with anti-
PKCδ antibodies or an isotype control (IgG) and subjected to in vitro kinase assays in the 
presence of histone H2B and [γ32P]ATP. Phospholabeled proteins were visualized by 
autoradiography. Immunoblots with PKCδ served as IP-loading control. 
 
 
 
 
 
26 
 
activity prior to this time point. This result suggests a potential role for PKCδ in Hsp27 
phosphorylation following 6 h apigenin treatment.   
 
3.3 Hsp27 phosphorylation is p38-dependent following 15 min apigenin 
treatment.  
  Phosphorylation profiles of Hsp27 and p38 following apigenin treatment (Fig 
3.1, Fig 3.2, respectively) indicate a potential role for p38 in the phosphorylation of 
Hsp27 at both 15 min and 6 h post-treatment. We first sought to determine the role of p38 
in Hsp27 phosphorlyation following a 15 min apigenin treatment. For this purpose, we 
aimed to determine the effects of pharmalogical inhibition of p38 on Hsp27 
phosphorylation 15 min post-apigenin treatment. THP-1 cells were pretreated with 10 
μM of the p38 inhibitor SB203580 or with DMSO as diluent control for 1 h. Following 
pretreatment, cells were treated with 50 μM apigenin for 15 min. Cell lysates were 
prepared and analyzed by immunoblot analysis (Fig 3.4). We found that pretreatment 
with SB203580 prior to a 15 min apigenin treatment reduced Hsp27 phosphorylation at 
both Ser-78 and Ser-82, as well as p38 phosphorylation (lane 3). These results suggest 
the necessity for p38 activity in Hsp27 phosphorylation following a 15 min apigenin 
treatment. 
 
3. 4 Hsp27 phosphorylation following 6 h apigenin treatment is characterized by 
residue specificity and dual pathways. 
 
Phosphorylation profiles of Hsp27 and p38 (Fig 3.1 and Fig 3.2, respectively) and 
the kinase activity of PKCδ (Fig 3.3) indicate potential roles for p38 and PKCδ in the 
phosphorylation of Hsp27 at 6 h post-apigenin treatment. Here we sought to determine  
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Figure 3.4 Hsp27 phosphorylation is p38 dependent following 15 min apigenin 
treatment 
 
Lysates from THP-1 cells cultured with 50 µM apigenin for 15 min following 1 h 
pretreatment with 10 µM of the p38 pharmalogical inhibitor SB203580 (lane 3). 
Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 Ser82, phospho-p38, total 
Hsp27, total p38 and β-Tubulin. 
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the role of p38 and PKCδ in Hsp27 phosphorylation following 6 h apigenin treatment. 
For this purpose, we first sought to determine the effects of pharmalogical inhibition of 
p38 and PKCδ on Hsp27 phosphorylation 6 h post-apigenin treatment. THP-1 cells were 
pretreated with either 10 μM of the p38 inhibitor SB203580, 15 μM of the PKCδ 
inhibitor rottlerin, both SB203580 and rottlerin, or DMSO as diluent control for 1 h. 
Following pretreatment, cells were treated with 50 μM apigenin for 6 h. Cell lysates were 
prepared and analyzed by immunoblot analysis. We found that pretreatment with 
SB203580 prior to 6 h apigenin treatment significantly reduced Hsp27 phosphorylation at 
both Ser-78 (Fig 3.5, lane 3) and Ser-82 (Fig 3.6, lane 3), indicating the necessity for p38 
activity in Hsp27 phosphorylation following 6 h apigenin treatment. In contrast, we found 
that pretreatment with rottlerin under similar conditions failed to reduce Hsp27 
phosphorylation at Ser-78 (Fig 3.5, lane 4). However, rottlerin pretreatment prior to 6 h 
apigenin treatment significantly reduced Hsp27 phosphorylation at the Ser-82 residue 
(Fig 3.6, lane 4), implicating a role for PKCδ in Hsp27 phosphorylation in a residue-
specific manner following 6 h apigenin treatment. As expected, pretreatment with the p38 
inhibitor SB203580 and the PKCδ inhibitor rottlerin significantly reduced Hsp27 
phosphorylation at both serine residues (Fig 3.5, Fig 3.6, lane 5). 
Hsp27 is known to be phosphorylated by p38 through MK2. In contrast, it has 
been shown that PKCδ can directly phosphorylate Hsp27 (66, 70). Our results suggest 
that PKCδ may directly phosphorylate Hsp27 in a residue-specific manner following 6 h 
apigenin treatment. To test this hypothesis, recombinant PKCδ was incubated with 
recombinant wild-type Hsp27 and [γ32P]ATP and analyzed by immunoblot analysis to  
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Figure 3.5 Hsp27 phosphorylation at Ser-78 is p38 dependent following 6 h apigenin 
treatment 
 
Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 h 
pretreatment with 10 µM of the p38 pharmalogical inhibitor SB203580 (lane 3), the 
PKCδ inhibitor rottlerin (lane 4), or both (lane 5). Immunoblots with phospho-Hsp27 
Ser-78 and total Hsp27. Densitometry data normalized by the loading control is 
represented as Mean ± SEM (N=6, Ë p ≤ 0.01, NS denotes non-statistical significance) 
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Figure 3.6 Hsp27 phosphorylation at Ser-82 is p38 and PKCδ dependent following 6 
h apigenin treatment 
 
Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 h 
pretreatment with 10 µM of the p38 pharmalogical inhibitor SB203580 (lane 3), the 
PKCδ inhibitor rottlerin (lane 4), or both (lane 5). Immunoblots with phospho-Hsp27 
Ser82 and total Hsp27. Densitometry data normalized by the loading control is 
represented as Mean ± SEM (N=6, Ë p ≤ 0.01 and ËË p ≤ 0.05) 
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determine PKCδ’s ability to phosphorylate Hsp27 (Fig 3.7). As expected, we found that 
PKCδ could not phosphorylate Hsp27 at Ser-78. In contrast, we found that PKCδ can 
directly phosphorylate Hsp27 at Ser-82. Together these findings suggest that PKCδ can 
phosphorylate Hsp27 selectively at Ser-82 in vitro. 
PKCδ has also been shown to act upstream of p38 activation (69). Therefore, we 
next sought to determine the relationship between PKCδ and p38 in apigenin-induced 
Hsp27 phosphorylation. For this purpose, THP-1 cells were treated with pharmalogical 
inhibitors of p38 and PKCδ as indicated above followed by 6 h treatment with apigenin. 
Cell lysates were prepared and first analyzed by immunoblot analysis (Fig 3.8A). We 
found that while the p38 inhibitor SB203580 expectantly reduces p38 phosphorylation 
(lane 3), the PKCδ inhibitor rottlerin fails to reduce p38 phosphorylation (lane 4), 
indicating that PKCδ is not an upstream regulator of p38 activation following 6 h 
apigenin treatment. We also analyzed the same samples by in vitro kinase assay to 
determine PKCδ’s kinase activity following pretreatment with p38 and PKCδ 
pharmalogical inhibitors (Fig 3.8B). As expected, we found that pretreatment with the 
PKCδ inhibitor rottlerin decreased PKCδ kinase activity following 6 h apigenin treatment 
(lane 5). Interestingly, pretreatment with the p38 inhibitor SB203580 (lane 4) also 
decreased PKCδ kinase activity, suggesting that p38 may act upstream to PKCδ and may 
provide an additional pathway through which p38 regulates Hsp27 phosphorylation.  
 
3.5 The effect of PKCδ on Hsp27 phosphorylation is independent of ERK 
activation 
 
As stated, ERK has been identified as both a kinase directly involved in the 
phosphorylation of MK2 (71) and as a substrate of PKCδ (72). Additionally, our results
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Figure 3.7 PKCδ selectively phosphorylates Hsp27 at Ser-82 in vitro. 
 
Recombinant PKCδ (+) or heat-inactivated recombinant PKCδ (-) was incubated with 
recombinant wild-type Hsp27 and [γ32P]ATP. Phospholabeled proteins were visualized 
by autoradiography. Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 Ser82, 
total Hsp27, and PKCδ. 
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Figure 3.8 p38 acts upstream of PKCδ following 6 h apigenin treatment. 
 
Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 h 
pretreatment with 10 µM of the p38 pharmalogical inhibitor SB203580 (lane 3 [A], lane 
4 [B]), the PKCδ inhibitor rottlerin (lane 4 [A], lane 5 [B]), or both (lane 5 [A], lane 6 
[B]). (A) Immunoblots with phospho-p38, p38 total, and β-Tubulin. (B) In vitro kinase 
assays of IP-PKCδ in the presence of H2B and [γ32P]ATP. Immunoblots with PKCδ 
served as loading control. 
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show that ERK phosphorylation is greatest at 6 h following apigenin treatment, indicating 
a potential role for ERK in apigenin-induced Hsp27 phosphorylation at 6 h. In order to 
assess the role of ERK in Hsp27 phosphorylation we first sought to determine if ERK 
was a downstream target of PKCδ. For this purpose, we sought to determine the effects 
of pharmalogical inhibition of PKCδ on ERK phosphorylation 6 h post-apigenin 
treatment. THP-1 cells were pretreated with 15 μM of the PKCδ inhibitor rottlerin or 
with DMSO as diluent control for 1 h. Following pretreatment, cells were treated with 50 
μM apigenin for 6 h. Cell lysates were prepared and analyzed by immunoblot analysis 
(Fig 3.9A). We found that inhibition of PKCδ with rottlerin reduced ERK 
phosphorylation following 6 h apigenin treatment (lane 3), identifying ERK as a potential 
downstream effector of PKCδ during apigenin-induced apoptosis.  
To further assess the relationship between PKCδ and ERK we sought to 
determine the effects of pharmalogical inhibition of ERK on Hsp27 phosphorylation. 
THP-1 cells were pretreated with 25 μM of the ERK inhibitor PD98059 or with DMSO 
as diluent control for 1 h. Following pretreatment, cells were treated with 50 μM apigenin 
for 6 h. Cell lysates were prepared and analyzed by immunoblot analysis (Fig 3.9B). We 
found that inhibition of ERK did not reduce Hsp27 phosphorylation at Ser-78 and Ser-82 
(lane 3). These findings suggest that a role for PKCδ in Hsp27 phosphorylation is 
independent of ERK, further providing evidence that PKCδ may directly phosphorylate 
Hsp27 during apigenin-induced apoptosis. 
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Figure 3.9 PKCδ effect on Hsp27 phosphorylation is independent of the downstream 
target ERK 
 
Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 h 
pretreatment with (A) 15 µM of the PKCδ inhibitor rottlerin (lane 3) or (B) 25 µM of the 
ERK pharmalogical inhibitor PD98059 (lane 3). Immunoblots with phospho-Hsp27 Ser-
78, phospho-Hsp27 Ser-82, phospho-ERK, total Hsp27, total ERK and β-Tubulin. 
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3.6 Generation of the PKCδ constitutively active catalytic fragment is not 
necessary for Hsp27 phosphorylation. 
 
 PKCδ has been shown to phosphorylate and activate caspase-3 (30). PKCδ has 
also been identified as a substrate of caspase-3 and its proteolytic cleavage results in a 
constitutively active catalytic domain necessary for apoptosis (31, 32). Therefore, 
caspase-3 may play a role in Hsp27 phosphorylation through PKCδ proteolytic 
activation. We first sought to determine the effect of inhibition of caspase-3 activity on 
PKCδ kinase activity. THP-1 cells were pretreated with 25 μM of the caspase-3 
inhibitory peptide DEVD-FMK or with DMSO as diluent control for 1 h. Following 
pretreatment, cells were treated with 50 μM apigenin for 6 h. Cell lysates were prepared 
and analyzed by an in vitro kinase assay to determine PKCδ’s kinase activity following 
pretreatment with the caspase-3 inhibitor (Fig 3.10A). We found that inhibition of 
caspase-3 activity decreases PKCδ kinase activity (lane 4), suggesting that PKCδ does 
not get cleaved to its constitutively active catalytic fragment in the presence of the 
caspase-3 inhibitory peptide. To further assess the role of caspase-3, we determined the 
effects of inhibition of caspase-3 activation on Hsp27 phosphorylation. THP-1 cells were 
treated with the inhibitory peptide of caspase-3 as indicated above followed by 6 h 
treatment with apigenin. Cell lystates were prepared and analyzed by immunoblot 
analysis (Fig 3.10B). We found that inhibition of caspase-3 activity failed to reduce 
Hsp27 phosphorylation at both serine residues, as well as p38 phosphorylation (lane 3), 
indicating that caspase-3 activity is not necessary for Hsp27 phosphorylation. DEVD-
AFC analysis of these samples confirms the efficiency of caspase-3 inhibition  
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Figure 3.10 PKCδ activity, but not Hsp27 and p38 phosphorylation, is dependent on 
caspase-3 activity following 6 h apigenin treatment 
 
Lysates from THP-1 cells cultured with 50 µM apigenin for 6 h following 1 hr 
pretreatment with 25 µM of the caspase-3 inhibitory peptide DEVD-FMK (lane 3 [A, B], 
lane 4 [C]). (A) In vitro kinase assays of IP-PKCδ in the presence of H2B and [γ32P]ATP.  
(B) Immunoblots with phospho-Hsp27 Ser78, phospho-Hsp27 Ser82, phospho-p38, total 
Hsp27, total p38 and β-Tubulin. (C) DEVD-AFC analysis of caspase-3 activity. 
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(Fig 3.10C). Together these results suggest that the non-constitutively active full-length 
PKCδ may phosphorylate Hsp27 at Ser-82 following apigenin treatment. 
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CHAPTER 4 
ROLE OF HSP27 PHOSPHORYLATION DURING APIGENIN-INDUCED 
APOPTOSIS 
 
Mitochondrial membrane depolarization occurs within minutes of exposure to 
apoptotic stimuli as a consequence of the mitochondrial permeability transition pore 
opening, preceding many other characteristic biochemical changes of apoptosis and 
serving as a point of no return of the apoptotic pathway (78). As a potent apoptotic 
stimulus, apigenin has been shown to induce mitochondrial membrane depolarization 
(46). Hsp27 is known to exhibit its anti-apoptotic activity at various points in the 
apoptotic pathway. One of the earliest anti-apoptotic functions of Hsp27 is its ability to 
prevent mitochondrial membrane depolarization (57). Therefore, Hsp27 may protect 
against apigenin-induced mitochondrial depolarization. Moreover, given that large, non-
phosphorylated Hsp27 oligomers have been suggested to be required for Hsp27’s anti-
apoptotic function (65), phosphorylation of Hsp27 may directly affect the protein’s 
ability to protect against mitochondrial depolarization and apoptosis. In this aim, we 
begin to study the role phosphorylation of Hsp27 plays during apigenin-induced 
phosphorylation. 
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4.1 Introduction of Hsp27 mutants into the 6xHis-tagged expression vector 
pQE32 and protein purification under denaturing conditions. 
  
 For future use to characterize Hsp27 direct interaction and association with 
targets, phospho-null Hsp27 3A (S15A, S78A, S82A) and phospho-mimic Hsp27 3D 
(S15D, S78D, S82D) recombinant proteins were prepared. For this purpose, the Hsp27 
3A and Hsp27 3D clones were excised from a pENTR/D-TOPO vector and introduced 
into a pQE32 vector in order to add a 6xHis-tag that can be used for affinity purification 
(Fig 4.1). The pENTR/D-TOPO vector is used to create clones using topoisomerase to 
ligate a small insert with only one small sticky end. Traditionally, the vector is used for 
recombination into a destination vector, such as pQE32. From glycerol stocks, bacterial 
colonies containting pENTR/D-TOPO-Hsp27 3A (AB566) and pENTR/D-TOPO-Hsp27 
3D (AB567), as well as pQE32 plasmids (AB262) were grown on antibiotic-resistant 
agar plates. From select colonies, plasmid DNA was isolated and digested with Bam HI 
and Sal 1 (Fig 4.2A) resulting in cut pQE32 (lane 1), Hsp27 3A fragment (lane 2, 648 
bp), and Hsp27 3D fragment (lane 3, 648 bp). DNA extraction from the agarose gel 
yielded purified linearized pQE32, Hsp27 3A insert, and Hsp27 3D insert (Fig 4.2B). 
Following DNA extraction, linearized pQE32 was ligated to Hsp27 3A and Hsp27 3D 
inserts in the presence of T4 ligase. The ligation was used to transform E. coli Top10F 
competent cells, and colonies were selected on LB-agar plates containing ampicillin.  
DNA was purified and screened by sequencing and restriction enzyme analysis with Bam 
HI and Sal 1 (Fig 4.2C) with positive clones yielding inserts of 648 bp (lane 1,2,3 
[pQE32-Hsp27 3A], lane 5,6 [pQE32-Hsp27 3D])  
E. coli containing clones pQE32-Hsp27 3A and pQE32-Hsp27 3D was used for 
protein purification. Expression of 6xHis-tagged Hsp27 phospho-
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Figure 4.1 Experimental scheme. 
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Figure 4.2 Ligation of Hsp27 3A and Hsp27 3D into the 6xHis-tagged pQE 32 vector 
 
(A) pQE 32, Topo-Hsp27 3A, Topo-Hsp27 3D were digested with Bam HI and Sal 1. (B) 
DNA extraction from the agarose gel yielded purified cut pQE32 and Hsp27 3A and 
Hsp27 3D inserts. (C) Following ligation of pQE32:Hsp27 3A and pQE32:Hsp27 3D and 
transformation into E. coli Top10F compentent cells, restriction digestion with Bam HI 
and Sal 1 identified positive clones (lane 1,2,3 [pQE32-Hsp27 3A], lane 5,6 [pQE32-
Hsp27 3D])  
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mutants was induced using IPTG and recombinant Hsp27 3A-6xHis and Hsp27 3D-
6xHis was purified from bacteria using a Ni2+-NTA affinity column (see Material and 
Methods). Using increasingly acidic buffers, substantial amount of protein was obtained 
in the first two elutions with buffer E (Fig 4.3A lanes 12, 13). Following dialysis and 
refolding, elution fractions containing mutant Hsp27 were analyzed by SDS-PAGE and 
quantitated by coomassie staining against a BSA gradient (Fig 4.3B) and identified by 
immunoblot with total Hsp27 (Fig 4.3C).  
 
4.2 Phosphorylation of Hsp27 is not required for Hsp27’s ability to protect 
against apigenin-induced mitochondrial membrane depolarization. 
 
Hsp27 is able to block apoptosis at different stages because of its interaction with 
different partners. The capacity of Hsp27 to interact with one or another partner seems to 
be determined by the oligomerization and phosphorylation status of the protein. At the 
earliest stages of apoptosis, Hsp27 is known to prevent mitochondrial depolarization 
through the suppression ROS formation by inhibiting PKCδ and upholding glutathione in 
its reduced form (34, 59). Therefore, phosphorylation of Hsp27 may serve to regulate 
Hsp27’s ability to prevent mitochondrial membrane depolarization. For this purpose, we 
sought to determine the effect of transfection of DNA encoding wild-type Hsp27, 
phospho-null Hsp27 3A and phospho-mimic Hsp27 3D into THP-1 cells on membrane 
depolarization. Twenty-four hours after transfection of empty vector (pCDNA3-5myc), 
vector containing wild type full-length Hsp27 (pCDNA3-Hsp27-wt-FL-5myc), full-
length Hsp27 3A (pCDNA3-Hsp27-3A-FL-5myc), or full-length Hsp27 3D (pCDNA3-
Hsp27-3D-FL-5myc), cells were treated with 50 μM apigenin for 1 h. Cells were then 
fixed with the mitochondrial membrane potential specific fluorescent probe JC-1 and  
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Figure 4.3 Purification of 6xHis-tagged Hsp27 under denaturing conditions 
 
(A) Coomassie stain of the purification of Hsp27 clones using a Ni2+-affinity column 
with elutions in a discontinuous pH gradient (buffer D pH 5.9; buffer E pH 4.5). 
Following refolding, elution fractions containing mutant Hsp27 were analyzed by SDS-
PAGE and (B) quantitated by coomassie staining against a BSA standard and (C) 
immunoblotted with total Hsp27. 
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analyzed by flow cytometry to detect color shifts in the dye upon formation of JC-1 
aggregates accompanying membrane depolarization (Fig 4.4). We found that apigenin 
treatment for 1 h increases mitochondrial membrane potential by 27% (Fig 4.4A). As 
expected, we found that introduction of Hsp27 wt-FL reduces mitochondrial 
depolarization to 6% (Fig 4.4B). Interestingly, we also found that both Hsp27 3A-FL and 
Hsp27 3D-FL (Fig 4.4C, Fig 4.4D, respectively) are able to reduce mitochondrial 
depolarization in the same magnitude, suggesting that phosphorylation of Hsp27 is not 
required for the protein’s ability to protect against apigenin-induced mitochondrial 
depolarization. 
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Figure 4.4 Hsp27’s ability to protect against mitochondrial depolarization is 
independent of its phosphorylation status 
 
THP-1 cells were transfected with (A) empty vector, (B) vector containing Hsp27-wt-FL, 
(C) Hsp27 3A (S15A-S78A-S82A), or (D) Hsp27 3D (S15D-S78D-S82D) and cultured 
with 50 µM apigenin for 1 h. Cells were fixed with JC-1 and analyzed by FACS analysis 
to determine changes in mitochondrial membrane potential. 
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CHAPTER 5 
 
DISCUSSION 
 
 Hsp27 is a chaperone that exhibits many anti-apoptotic functions. Central to 
Hsp27 anti-apoptotic function is the dynamic relationship between phosphorylation, 
oligomerization, and association with target proteins (55, 66, 73, 74). In particular, Hsp27 
is known to regulate many of the molecules involved in caspase-dependent apoptosis (60-
63). During caspase-dependent apoptosis, external signals transduced through death 
receptors or internal signals transduced through mitochondrial dysfunction generate a 
signaling cascade that culminates in the proteolytic activation of effector caspases 
responsible for facilitating the characteristic biochemical changes observed during 
apoptosis (3). Among the signals more commonly responsible for apoptosis are cytotoxic 
drugs. Recently, our lab identified a plant flavonoid, apigenin, that has anti-cancer and 
anti-inflammatory properties (47). We showed that apigenin is a potent pro-apoptotic 
molecule in leukemia cells through localization to the mitochondria and induction of 
apoptosis in a PKCδ and caspase-depedent manner. In this work, we built on the model 
of apigenin-induced apoptosis with an emphasis on the regulation and role of Hsp27 
phosphorylation.  
Since many of the functions attributed to Hsp27 require its phosphorylation (74, 
79, 80), the identification of the protein kinases that mediate Hsp27 phosphorylation is 
critical for understanding the regulation of Hsp27’s multiple cellular functions. The 
mitogen-activated protein kinase p38 is known to be activated in response to 
chemotherapeutic drugs as a pro-apoptotic molecule (26) and is widely regarded as an 
upstream kinase of Hsp27 through activation of MK2 (81). Thus, p38 was investigated as 
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a potential kinase involved in apigenin-induced Hsp27 phosphorylation. Accordingly, we 
demonstrate that Hsp27 phosphorylation at Ser-78 and Ser-82 is p38 dependent following 
15 min and 6 h apigenin treatment (Fig 3.4 – Fig 3.6). In addition, we exhibit that p38 
activity following 6 h apigenin treatment is independent of caspase-3 activity (Fig 
3.10B), consistent with findings that p38 activity is not essential for apigenin-induced 
apoptosis (47).  PKCδ has also been implicated in Hsp27 phosphorylation, albeit in a 
stimulus-dependent manner (82). PKCδ can act as either pro-apoptotic molecule or anti-
apoptotic molecule depending on the stimulus (77). Our lab has shown that 
PKCδ associates with and phosphorylates caspase-3, promoting apoptosis (30). Here, we 
identified a role for PKCδ in apigenin-induced Hsp27 phosphorylation. We demonstrate 
that PKCδ can directly and selectively phosphorylate Hsp27 at Ser-82 (Fig 3.7).  We also 
find that PKCδ may act downstream of p38 in a pathway parallel to p38 activation of 
MK2 at 6 h post-apigenin treatment (Fig. 3.8B).  In addition, we find that PKCδ exhibits 
its effect on Hsp27 phosphorylation independent of both downstream ERK (Fig 3.9) and 
cleavage by caspase-3 (Fig 3.10), suggesting that full-length PKCδ may directly 
phosphorylate Hsp27 at Ser-82 following 6 h apigenin treatment as a result of p38 
activation.  
The role played by Hsp27 as an anti-apoptotic molecule appears to be largely 
determined by its oligomerization and thus, phosphorylation state.  It has been suggested 
that large non-phosphorylated oligomers are the structural organization required for 
Hsp27’s caspase-dependent anti-apoptotic activity (65). However, phosphorylation of 
Hsp27 results in a shift from large, nonphosphorylated oligomers to smaller 
phosphorylated multimers such as dimers and this shift attenuates Hsp27’s affinity for its 
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substrates (74). Therefore, phosphorylation may disrupt the anti-apoptotic activity of 
Hsp27. However, our findings suggest that Hsp27’s ability to protect against apigenin-
induced mitochondrial membrane depolarization (Fig 4.4) is independent of the protein’s 
phosphorylation state. We find that the Hsp27 wt can protect against apigenin-induced 
mitochondrial depolarization. Moreover, phospho-null Hsp27 3A mutant and phospho-
mimic Hsp27 3D mutant have similar cytoprotective abilities. Therefore; results are 
consistent with previous suggestions that large non-phosphorylated oligomers are 
required for Hsp27’s anti-apoptotic activity at this early event. 
According to our model of apigenin-induced apoptosis, Hsp27 is phosphorylated 
at both Ser-78 and Ser-82 by p38 through MK2 at 15 min and 6 h and at Ser-82 by p38 
through PKCδ at 6 h. The bimodal phosphorylation of Hsp27 during apigenin-induced 
apoptosis is a distinct mechanism of Hsp27 regulation. The underlying significance of 
our findings is that different methods of regulation of Hsp27 phosphorylation could result 
in different fates for the phosphorylated molecule. Our findings suggest that early and 
late phosphorylation of Hsp27 following apigenin treatment represent distinct, and 
perhaps mechanistically important, roles for the phosphorylated molecule in response to 
apigenin-induced apoptosis. Apigenin-induced early phosphorylation may play either an 
anti-apoptotic or pro-apoptotic role within the cell. Upon phosphorylation by the p38 
MAPK pathway, Hsp27 has been shown to protect cells from oxidative stress by 
upholding glutathione in its reduced form (83) as well as stabilizing actin filament 
dynamics following stress (80, 84). These functions may protect the cell against 
mitochondrial dysfunction as both oxidative stress and actin destabilization contribute to 
mitochondrial dysfunction and apoptosis (85, 86). However, our results indicate that 
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Hsp27 phosphorylation is not essential for the protein’s ability to protect against 
mitochondrial depolarization, suggesting that early Hsp27 phosphorylation may be a 
stress response rather than an anti-apoptotic response. Additionally, early Hsp27 
phosphorylation may play a pro-apoptotic role through its ability to cause dissociation of 
the molecule from its target proteins. In particular, Hsp27 phosphorylation may play a 
role in dissociation from its target proteins during caspase-dependent apoptosis. Our lab 
has shown using recombinant proteins that cleavage of the prodomain of caspase-3 
occurs as early as 45 min following the addition of caspase-9 and that addition of Hsp27 
attenuates this cleavage (64). Therefore, early phosphorylation of Hsp27 may play a role 
in promoting caspase-dependent apoptosis by alleviating Hsp27 inhibition of caspase-3. 
In addition, our lab has shown that Hsp27 is found mostly in the nucleus at 8 h during 
spontaneous monocyte apoptosis. This may suggest a role for the late Hsp27 
phosphorylation as phosphorylation of Hsp27 has been shown to affect the protein’s 
ability to translocate to the nucleus (79, 87). Additionally, the ability to selectively 
phosphorylate Hsp27 at either Ser-78 or Ser-82 following 6 h apigenin treatment could 
result in drastically different cellular fates. Indeed, specific phosphorylation of Hsp27 at 
Ser-78 or Ser-82 has been shown to play integral roles in cellular fate (88-90). Therefore, 
the phosphorylation of Hsp27 at Ser-82 by PKCδ may play a yet uncharacterized role in 
Hsp27 regulation.  Interestingly, it has been shown that dissociation of PMA-induced 
Hsp27 aggregates can be prevented by PKC inhibitors, while p38 inhibitors achieve a 
significantly smaller effect (82). Thus, PKCδ phosphorylation at Ser-82 may play an 
essential role in the regulation of Hsp27 through phosphorylation-induced dissociation of 
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Hsp27 into smaller multimers and dissociation of the molecule from a yet unidentified 
target at this time.  
The pro-apoptotic roles of apigenin highlight the ever growing focus on 
chemopreventive roles of naturally-derived dietary compounds such as flavonoids. As an 
antioxidant, apigenin serve to regulate intracellular redox balance. However, apigenin is 
also potent inducer of the apoptotic pathway and the study of apigenin-induced apoptosis 
helps us to understand the molecular mechanisms flavonoids use to regulate cell fate and 
the potential use of flavonoids as chemotherapeutic agents. 
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Figure 5.1 Working Model 
 
 
 
 
53 
 
ACKNOWLEDGEMENTS 
Thanks to Dr. Andrea Doseff for her guidance, opportunity, contribution, and 
critical reading of this thesis.  Thanks also to Dr. Martha Elba Gonzalez-Mejia and Oliver 
Voss for their contributions to this work, and the Doseff lab members for their aid and 
support. This research was supported by RO1HL075040-01 and NSF-MCB-0542244 to 
AID and the OSU College of Biological Sciences Dean’s Undergraduate Research Fund 
and Mayer’s Summer Research Internship to EJM. 
 
 
54 
 
REFERENCES 
(1) Ellis, H. M., and Horvitz, H. R. (1986) Genetic control of programmed cell death 
in the nematode C. elegans. Cell 44, 817-29. 
(2) Pierce, G. B., Gramzinski, R. A., and Parchment, R. E. (1989) Programmed cell 
death in the blastocyst. Ann N Y Acad Sci 567, 182-6. 
(3) Thornberry, N. A., and Lazebnik, Y. (1998) Caspases: enemies within. Science 
281, 1312-6. 
(4) Friedlander, R. M. (2003) Apoptosis and caspases in neurodegenerative diseases. 
N Engl J Med 348, 1365-75. 
(5) Rudin, C. M., and Thompson, C. B. (1997) Apoptosis and disease: regulation and 
clinical relevance of programmed cell death. Annu Rev Med 48, 267-81. 
(6) Savill, J. (2000) Apoptosis in resolution of inflammation. Kidney Blood Press Res 
23, 173-4. 
(7) Dive, C., and Hickman, J. A. (1991) Drug-target interactions: only the first step in 
the commitment to a programmed cell death? Br J Cancer 64, 192-6. 
(8) Hampton, M. B., Fadeel, B., and Orrenius, S. (1998) Redox regulation of the 
caspases during apoptosis. Ann N Y Acad Sci 854, 328-35. 
(9) Salvesen, G. S., and Dixit, V. M. (1997) Caspases: intracellular signaling by 
proteolysis. Cell 91, 443-6. 
(10) Adams, J. M., and Cory, S. (2002) Apoptosomes: engines for caspase activation. 
Curr Opin Cell Biol 14, 715-20. 
(11) Stennicke, H. R., and Salvesen, G. S. (1997) Biochemical characteristics of 
caspases-3, -6, -7, and -8. J Biol Chem 272, 25719-23. 
(12) Cohen, G. M. (1997) Caspases: the executioners of apoptosis. Biochem J 326 (Pt 
1), 1-16. 
(13) Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D. M., Timkey, T., 
Garcia-Calvo, M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. 
P., Chapman, K. T., and Nicholson, D. W. (1997) A combinatorial approach 
defines specificities of members of the caspase family and granzyme B. 
Functional relationships established for key mediators of apoptosis. J Biol Chem 
272, 17907-11. 
(14) Muzio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S., and Dixit, V. M. 
(1998) An induced proximity model for caspase-8 activation. J Biol Chem 273, 
2926-30. 
(15) Peter, M. E., and Krammer, P. H. (1998) Mechanisms of CD95 (APO-1/Fas)-
mediated apoptosis. Curr Opin Immunol 10, 545-51. 
(16) Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. 
S., and Wang, X. (1997) Cytochrome c and dATP-dependent formation of Apaf-
1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479-89. 
(17) Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998) Bid, a Bcl2 
interacting protein, mediates cytochrome c release from mitochondria in response 
to activation of cell surface death receptors. Cell 94, 481-90. 
(18) Saybasili, H., Yuksel, M., Haklar, G., and Yalcin, A. S. (2001) Effect of 
mitochondrial electron transport chain inhibitors on superoxide radical generation 
in rat hippocampal and striatal slices. Antioxid Redox Signal 3, 1099-104. 
55 
 
(19) Bergamini, C. M., Gambetti, S., Dondi, A., and Cervellati, C. (2004) Oxygen, 
reactive oxygen species and tissue damage. Curr Pharm Des 10, 1611-26. 
(20) Slee, E. A., Harte, M. T., Kluck, R. M., Wolf, B. B., Casiano, C. A., Newmeyer, 
D. D., Wang, H. G., Reed, J. C., Nicholson, D. W., Alnemri, E. S., Green, D. R., 
and Martin, S. J. (1999) Ordering the cytochrome c-initiated caspase cascade: 
hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-
dependent manner. J Cell Biol 144, 281-92. 
(21) Buendia, B., Santa-Maria, A., and Courvalin, J. C. (1999) Caspase-dependent 
proteolysis of integral and peripheral proteins of nuclear membranes and nuclear 
pore complex proteins during apoptosis. J Cell Sci 112 (Pt 11), 1743-53. 
(22) Rao, L., Perez, D., and White, E. (1996) Lamin proteolysis facilitates nuclear 
events during apoptosis. J Cell Biol 135, 1441-55. 
(23) Rudel, T., and Bokoch, G. M. (1997) Membrane and morphological changes in 
apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276, 
1571-4. 
(24) Olson, J. M., and Hallahan, A. R. (2004) p38 MAP kinase: a convergence point in 
cancer therapy. Trends Mol Med 10, 125-9. 
(25) Bulavin, D. V., Saito, S., Hollander, M. C., Sakaguchi, K., Anderson, C. W., 
Appella, E., and Fornace, A. J., Jr. (1999) Phosphorylation of human p53 by p38 
kinase coordinates N-terminal phosphorylation and apoptosis in response to UV 
radiation. Embo J 18, 6845-54. 
(26) Deacon, K., Mistry, P., Chernoff, J., Blank, J. L., and Patel, R. (2003) p38 
Mitogen-activated protein kinase mediates cell death and p21-activated kinase 
mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol 
Biol Cell 14, 2071-87. 
(27) Doseff, A. I., Baker, J. H., Jr., Bourgeois, T. A., and Wewers, M. D. (2003) 
Interleukin-4-induced apoptosis entails caspase activation and suppression of 
extracellular signal-regulated kinase phosphorylation. Am J Respir Cell Mol Biol 
29, 367-74. 
(28) Van Dross, R., Xue, Y., Knudson, A., and Pelling, J. C. (2003) The 
chemopreventive bioflavonoid apigenin modulates signal transduction pathways 
in keratinocyte and colon carcinoma cell lines. J Nutr 133, 3800S-3804S. 
(29) Brodie, C., and Blumberg, P. M. (2003) Regulation of cell apoptosis by protein 
kinase c delta. Apoptosis 8, 19-27. 
(30) Voss, O. H., Kim, S., Wewers, M. D., and Doseff, A. I. (2005) Regulation of 
monocyte apoptosis by the protein kinase Cdelta-dependent phosphorylation of 
caspase-3. J Biol Chem 280, 17371-9. 
(31) Ghayur, T., Hugunin, M., Talanian, R. V., Ratnofsky, S., Quinlan, C., Emoto, Y., 
Pandey, P., Datta, R., Huang, Y., Kharbanda, S., Allen, H., Kamen, R., Wong, 
W., and Kufe, D. (1996) Proteolytic activation of protein kinase C delta by an 
ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 184, 
2399-404. 
(32) Reyland, M. E., Anderson, S. M., Matassa, A. A., Barzen, K. A., and Quissell, D. 
O. (1999) Protein kinase C delta is essential for etoposide-induced apoptosis in 
salivary gland acinar cells. J Biol Chem 274, 19115-23. 
56 
 
(33) Majumder, P. K., Pandey, P., Sun, X., Cheng, K., Datta, R., Saxena, S., 
Kharbanda, S., and Kufe, D. (2000) Mitochondrial translocation of protein kinase 
C delta in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem 
275, 21793-6. 
(34) Lee, Y. J., Lee, D. H., Cho, C. K., Chung, H. Y., Bae, S., Jhon, G. J., Soh, J. W., 
Jeoung, D. I., Lee, S. J., and Lee, Y. S. (2005) HSP25 inhibits radiation-induced 
apoptosis through reduction of PKCdelta-mediated ROS production. Oncogene 
24, 3715-25. 
(35) Li, P. F., Maasch, C., Haller, H., Dietz, R., and von Harsdorf, R. (1999) 
Requirement for protein kinase C in reactive oxygen species-induced apoptosis of 
vascular smooth muscle cells. Circulation 100, 967-73. 
(36) Manach, C., Scalbert, A., Morand, C., Remesy, C., and Jimenez, L. (2004) 
Polyphenols: food sources and bioavailability. Am J Clin Nutr 79, 727-47. 
(37) Yang, C. S., Landau, J. M., Huang, M. T., and Newmark, H. L. (2001) Inhibition 
of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21, 381-
406. 
(38) Le Marchand, L. (2002) Cancer preventive effects of flavonoids--a review. 
Biomed Pharmacother 56, 296-301. 
(39) Middleton, E., Jr., Kandaswami, C., and Theoharides, T. C. (2000) The effects of 
plant flavonoids on mammalian cells: implications for inflammation, heart 
disease, and cancer. Pharmacol Rev 52, 673-751. 
(40) Wang, H. K. (2000) The therapeutic potential of flavonoids. Expert Opin Investig 
Drugs 9, 2103-19. 
(41) Harmon, A. W., and Patel, Y. M. (2004) Naringenin inhibits glucose uptake in 
MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. 
Breast Cancer Res Treat 85, 103-10. 
(42) Way, T. D., Kao, M. C., and Lin, J. K. (2004) Apigenin induces apoptosis through 
proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer 
cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 
279, 4479-89. 
(43) Wang, W., Heideman, L., Chung, C. S., Pelling, J. C., Koehler, K. J., and Birt, D. 
F. (2000) Cell-cycle arrest at G2/M and growth inhibition by apigenin in human 
colon carcinoma cell lines. Mol Carcinog 28, 102-10. 
(44) Wang, I. K., Lin-Shiau, S. Y., and Lin, J. K. (1999) Induction of apoptosis by 
apigenin and related flavonoids through cytochrome c release and activation of 
caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 35, 1517-25. 
(45) Morrissey, C., O'Neill, A., Spengler, B., Christoffel, V., Fitzpatrick, J. M., and 
Watson, R. W. (2005) Apigenin drives the production of reactive oxygen species 
and initiates a mitochondrial mediated cell death pathway in prostate epithelial 
cells. Prostate 63, 131-42. 
(46) Miyoshi, N., Naniwa, K., Yamada, T., Osawa, T., and Nakamura, Y. (2007) 
Dietary flavonoid apigenin is a potential inducer of intracellular oxidative stress: 
the role in the interruptive apoptotic signal. Arch Biochem Biophys 466, 274-82. 
(47) Vargo, M. A., Voss, O. H., Poustka, F., Cardounel, A. J., Grotewold, E., and 
Doseff, A. I. (2006) Apigenin-induced-apoptosis is mediated by the activation of 
PKCdelta and caspases in leukemia cells. Biochem Pharmacol 72, 681-92. 
57 
 
(48) Lindquist, S., and Craig, E. A. (1988) The heat-shock proteins. Annu Rev Genet 
22, 631-77. 
(49) Cuesta, R., Laroia, G., and Schneider, R. J. (2000) Chaperone hsp27 inhibits 
translation during heat shock by binding eIF4G and facilitating dissociation of 
cap-initiation complexes. Genes Dev 14, 1460-70. 
(50) Ehrnsperger, M., Graber, S., Gaestel, M., and Buchner, J. (1997) Binding of non-
native protein to Hsp25 during heat shock creates a reservoir of folding 
intermediates for reactivation. Embo J 16, 221-9. 
(51) Jakob, U., Gaestel, M., Engel, K., and Buchner, J. (1993) Small heat shock 
proteins are molecular chaperones. J Biol Chem 268, 1517-20. 
(52) Merck, K. B., Horwitz, J., Kersten, M., Overkamp, P., Gaestel, M., Bloemendal, 
H., and de Jong, W. W. (1993) Comparison of the homologous carboxy-terminal 
domain and tail of alpha-crystallin and small heat shock protein. Mol Biol Rep 18, 
209-15. 
(53) van Montfort, R. L., Basha, E., Friedrich, K. L., Slingsby, C., and Vierling, E. 
(2001) Crystal structure and assembly of a eukaryotic small heat shock protein. 
Nat Struct Biol 8, 1025-30. 
(54) Ito, H., Kamei, K., Iwamoto, I., Inaguma, Y., Nohara, D., and Kato, K. (2001) 
Phosphorylation-induced change of the oligomerization state of alpha B-
crystallin. J Biol Chem 276, 5346-52. 
(55) Rogalla, T., Ehrnsperger, M., Preville, X., Kotlyarov, A., Lutsch, G., Ducasse, C., 
Paul, C., Wieske, M., Arrigo, A. P., Buchner, J., and Gaestel, M. (1999) 
Regulation of Hsp27 oligomerization, chaperone function, and protective activity 
against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol 
Chem 274, 18947-56. 
(56) MacRae, T. H. (2000) Structure and function of small heat shock/alpha-crystallin 
proteins: established concepts and emerging ideas. Cell Mol Life Sci 57, 899-913. 
(57) Paul, C., and Arrigo, A. P. (2000) Comparison of the protective activities 
generated by two survival proteins: Bcl-2 and Hsp27 in L929 murine fibroblasts 
exposed to menadione or staurosporine. Exp Gerontol 35, 757-66. 
(58) Lee, Y. J., Cho, H. N., Jeoung, D. I., Soh, J. W., Cho, C. K., Bae, S., Chung, H. 
Y., Lee, S. J., and Lee, Y. S. (2004) HSP25 overexpression attenuates oxidative 
stress-induced apoptosis: roles of ERK1/2 signaling and manganese superoxide 
dismutase. Free Radic Biol Med 36, 429-44. 
(59) Arrigo, A. P., Virot, S., Chaufour, S., Firdaus, W., Kretz-Remy, C., and Diaz-
Latoud, C. (2005) Hsp27 consolidates intracellular redox homeostasis by 
upholding glutathione in its reduced form and by decreasing iron intracellular 
levels. Antioxid Redox Signal 7, 414-22. 
(60) Charette, S. J., Lavoie, J. N., Lambert, H., and Landry, J. (2000) Inhibition of 
Daxx-mediated apoptosis by heat shock protein 27. Mol Cell Biol 20, 7602-12. 
(61) Concannon, C. G., Orrenius, S., and Samali, A. (2001) Hsp27 inhibits cytochrome 
c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome 
c. Gene Expr 9, 195-201. 
(62) Garrido, C., Bruey, J. M., Fromentin, A., Hammann, A., Arrigo, A. P., and 
Solary, E. (1999) HSP27 inhibits cytochrome c-dependent activation of 
procaspase-9. Faseb J 13, 2061-70. 
58 
 
(63) Havasi, A., Li, Z., Wang, Z., Martin, J. L., Botla, V., Ruchalski, K., Schwartz, J. 
H., and Borkan, S. C. (2008) Hsp27 inhibits Bax activation and apoptosis via a 
phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem 283, 12305-13. 
(64) Voss, O. H., Batra, S., Kolattukudy, S. J., Gonzalez-Mejia, M. E., Smith, J. B., 
and Doseff, A. I. (2007) Binding of caspase-3 prodomain to heat shock protein 27 
regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J Biol 
Chem 282, 25088-99. 
(65) Bruey, J. M., Paul, C., Fromentin, A., Hilpert, S., Arrigo, A. P., Solary, E., and 
Garrido, C. (2000) Differential regulation of HSP27 oligomerization in tumor 
cells grown in vitro and in vivo. Oncogene 19, 4855-63. 
(66) Lee, Y. J., Lee, D. H., Cho, C. K., Bae, S., Jhon, G. J., Lee, S. J., Soh, J. W., and 
Lee, Y. S. (2005) HSP25 inhibits protein kinase C delta-mediated cell death 
through direct interaction. J Biol Chem 280, 18108-19. 
(67) Landry, J., Lambert, H., Zhou, M., Lavoie, J. N., Hickey, E., Weber, L. A., and 
Anderson, C. W. (1992) Human HSP27 is phosphorylated at serines 78 and 82 by 
heat shock and mitogen-activated kinases that recognize the same amino acid 
motif as S6 kinase II. J Biol Chem 267, 794-803. 
(68) Stokoe, D., Engel, K., Campbell, D. G., Cohen, P., and Gaestel, M. (1992) 
Identification of MAPKAP kinase 2 as a major enzyme responsible for the 
phosphorylation of the small mammalian heat shock proteins. FEBS Lett 313, 
307-13. 
(69) Takai, S., Matsushima-Nishiwaki, R., Tokuda, H., Yasuda, E., Toyoda, H., 
Kaneoka, Y., Yamaguchi, A., Kumada, T., and Kozawa, O. (2007) Protein kinase 
C delta regulates the phosphorylation of heat shock protein 27 in human 
hepatocellular carcinoma. Life Sci 81, 585-91. 
(70) Maizels, E. T., Peters, C. A., Kline, M., Cutler, R. E., Jr., Shanmugam, M., and 
Hunzicker-Dunn, M. (1998) Heat-shock protein-25/27 phosphorylation by the 
delta isoform of protein kinase C. Biochem J 332 (Pt 3), 703-12. 
(71) Coxon, P. Y., Rane, M. J., Uriarte, S., Powell, D. W., Singh, S., Butt, W., Chen, 
Q., and McLeish, K. R. (2003) MAPK-activated protein kinase-2 participates in 
p38 MAPK-dependent and ERK-dependent functions in human neutrophils. Cell 
Signal 15, 993-1001. 
(72) Denhardt, D. T. (1996) Signal-transducing protein phosphorylation cascades 
mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex 
signalling. Biochem J 318 (Pt 3), 729-47. 
(73) Lambert, H., Charette, S. J., Bernier, A. F., Guimond, A., and Landry, J. (1999) 
HSP27 multimerization mediated by phosphorylation-sensitive intermolecular 
interactions at the amino terminus. J Biol Chem 274, 9378-85. 
(74) Zheng, C., Lin, Z., Zhao, Z. J., Yang, Y., Niu, H., and Shen, X. (2006) MAPK-
activated protein kinase-2 (MK2)-mediated formation and phosphorylation-
regulated dissociation of the signal complex consisting of p38, MK2, Akt, and 
Hsp27. J Biol Chem 281, 37215-26. 
(75) Landry, J., Chretien, P., Laszlo, A., and Lambert, H. (1991) Phosphorylation of 
HSP27 during development and decay of thermotolerance in Chinese hamster 
cells. J Cell Physiol 147, 93-101. 
59 
 
(76) Raman, M., Chen, W., and Cobb, M. H. (2007) Differential regulation and 
properties of MAPKs. Oncogene 26, 3100-12. 
(77) Reyland, M. E. (2007) Protein kinase Cdelta and apoptosis. Biochem Soc Trans 
35, 1001-4. 
(78) Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssiere, J. L., Petit, P. X., 
and Kroemer, G. (1995) Reduction in mitochondrial potential constitutes an early 
irreversible step of programmed lymphocyte death in vivo. J Exp Med 181, 1661-
72. 
(79) Geum, D., Son, G. H., and Kim, K. (2002) Phosphorylation-dependent cellular 
localization and thermoprotective role of heat shock protein 25 in hippocampal 
progenitor cells. J Biol Chem 277, 19913-21. 
(80) Guay, J., Lambert, H., Gingras-Breton, G., Lavoie, J. N., Huot, J., and Landry, J. 
(1997) Regulation of actin filament dynamics by p38 map kinase-mediated 
phosphorylation of heat shock protein 27. J Cell Sci 110 (Pt 3), 357-68. 
(81) Chang, L., and Karin, M. (2001) Mammalian MAP kinase signalling cascades. 
Nature 410, 37-40. 
(82) Kato, K., Ito, H., Iwamoto, I., Lida, K., and Inaguma, Y. (2001) Protein kinase 
inhibitors can suppress stress-induced dissociation of Hsp27. Cell Stress 
Chaperones 6, 16-20. 
(83) Jackson, R. M., and Garcia-Rojas, R. (2008) Kinase activity, heat shock protein 
27 phosphorylation, and lung epithelial cell glutathione. Exp Lung Res 34, 245-
62. 
(84) Landry, J., and Huot, J. (1995) Modulation of actin dynamics during stress and 
physiological stimulation by a signaling pathway involving p38 MAP kinase and 
heat-shock protein 27. Biochem Cell Biol 73, 703-7. 
(85) Zucker, B., Hanusch, J., and Bauer, G. (1997) Glutathione depletion in fibroblasts 
is the basis for apoptosis-induction by endogenous reactive oxygen species. Cell 
Death Differ 4, 388-95. 
(86) Tang, H. L., Le, A. H., and Lung, H. L. (2006) The increase in mitochondrial 
association with actin precedes Bax translocation in apoptosis. Biochem J 396, 1-
5. 
(87) Bryantsev, A. L., Kurchashova, S. Y., Golyshev, S. A., Polyakov, V. Y., 
Wunderink, H. F., Kanon, B., Budagova, K. R., Kabakov, A. E., and Kampinga, 
H. H. (2007) Regulation of stress-induced intracellular sorting and chaperone 
function of Hsp27 (HspB1) in mammalian cells. Biochem J 407, 407-17. 
(88) Rane, M. J., Pan, Y., Singh, S., Powell, D. W., Wu, R., Cummins, T., Chen, Q., 
McLeish, K. R., and Klein, J. B. (2003) Heat shock protein 27 controls apoptosis 
by regulating Akt activation. J Biol Chem 278, 27828-35. 
(89) Yuan, J., and Rozengurt, E. (2008) PKD, PKD2, and p38 MAPK mediate Hsp27 
serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 
cells. J Cell Biochem 103, 648-62. 
(90) Niwa, M., Hotta, K., Hara, A., Hirade, K., Ito, H., Kato, K., and Kozawa, O. 
(2006) TNF-alpha decreases hsp 27 in human blood mononuclear cells: 
involvement of protein kinase c. Life Sci 80, 181-6. 
 
 
